{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:19:52Z","timestamp":1790309992834,"version":"4.1.0"},"reference-count":283,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Janus kinase (JAK) inhibitors are being increasingly used in inflammatory bowel diseases (IBDs). In the present review we raise a series of practical questions on JAK inhibitors in IBD and provide clear and concise answers. We performed a bibliographic search to identify studies assessing the role of JAK inhibitors in IBD. The key conclusions are summarized as follows. Upadacitinib has shown favorable efficacy outcomes in ulcerative colitis relative to other JAK inhibitors, although this conclusion requires confirmation through randomized trials. Extended induction can benefit patients with partial response. Real-world data support the use of JAK inhibitors in pediatric and older adults with IBD. JAK inhibitor efficacy appears unaffected by body mass index. JAK inhibitors may offer considerably high colectomy-free rates in acute severe ulcerative colitis. Interruption of therapy should be cautious, as maintenance seems key to sustained remission. Dose re-escalation can recapture response in over half of patients with loss of efficacy. Switching between JAK inhibitors, especially from tofacitinib to upadacitinib, is a viable strategy. Upadacitinib appears promising in the treatment of refractory perianal fistulizing Crohn\u2019s disease. JAK inhibitors may also be an option in refractory pouchitis. Combination therapy with JAK inhibitors and biologics may be beneficial in refractory IBD, though more studies are needed. JAK inhibitors appear effective in some extraintestinal dermatologic manifestations. Pretreatment screening for latent tuberculosis is advised. JAK inhibitors cause reversible, dose-dependent cholesterol increases without consistent evidence of a clear impact on cardiovascular risk, but monitoring is advised. Use in pregnancy is discouraged due to potential risks, and breastfeeding is contraindicated because of drug excretion in milk.<\/jats:p>","DOI":"10.1093\/ibd\/izaf273","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:33:10Z","timestamp":1761046390000},"page":"775-802","source":"Crossref","is-referenced-by-count":5,"title":["Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P","family":"Gisbert","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa, Universidad Aut\u00f3noma de Madrid, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa, Universidad Aut\u00f3noma de Madrid, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2026040214063208600_izaf273-B1","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.crphar.2022.100096","article-title":"User\u2019s guide to JAK inhibitors in inflammatory bowel disease","volume":"3","author":"Spiewak","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2026040214063208600_izaf273-B2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"2026040214063208600_izaf273-B3","doi-asserted-by":"crossref","DOI":"10.3390\/ph18050740","article-title":"State-of-the-art evidence for clinical outcomes and therapeutic implications of Janus kinase inhibitors in moderate-to-severe ulcerative colitis: a narrative review","volume":"18","author":"Choi","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026040214063208600_izaf273-B4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/flgastro-2020-101502","article-title":"Guideline review: tofacitinib for adults with moderately to severely active ulcerative colitis\u2014NICE guidance","volume":"12","author":"Nwaogu","year":"2021","journal-title":"Frontline Gastroenterol"},{"key":"2026040214063208600_izaf273-B5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/apt.17185","article-title":"Review article: guide to tofacitinib dosing in patients with ulcerative colitis","volume":"56","author":"Irving","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17474124.2023.2172399","article-title":"A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis","volume":"17","author":"Law","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B7","doi-asserted-by":"crossref","first-page":"17562848231158235","DOI":"10.1177\/17562848231158235","article-title":"Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis","volume":"16","author":"Ernest-Suarez","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"2026040214063208600_izaf273-B8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14656566.2024.2333964","article-title":"Upadacitinib in Crohn\u2019s disease","volume":"25","author":"Dignass","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026040214063208600_izaf273-B9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.14309\/ajg.0000000000002598","article-title":"A practical guide to the use of upadacitinib in ulcerative colitis and Crohn\u2019s disease","volume":"119","author":"Weiss","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ecco-jcc\/jjab206","article-title":"Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis","volume":"16","author":"D\u2019Amico","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"2026040214063208600_izaf273-B13","first-page":"727","article-title":"Are all janus kinase inhibitors for inflammatory bowel disease the same?","volume":"19","author":"Honap","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026040214063208600_izaf273-B14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/apt.18406","article-title":"Comparative efficacy and safety of three janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan","volume":"61","author":"Akiyama","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B15","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.14309\/ajg.0000000000002746","article-title":"One-year comparative effectiveness of upadacitinib vs tofacitinib for ulcerative colitis: a multicenter cohort study","volume":"119","author":"Dalal","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B17","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.3390\/jcm13247804","article-title":"Real-world effectiveness and safety of selective JAK inhibitors in ulcerative colitis and Crohn\u2019s disease: a retrospective, multicentre study","volume":"13","author":"Farkas","year":"2024","journal-title":"J Clin Med"},{"key":"2026040214063208600_izaf273-B18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5217\/ir.2024.00148","article-title":"Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor \u03b1 antibody","volume":"23","author":"Ikenouchi","year":"2025","journal-title":"Intest Res"},{"key":"2026040214063208600_izaf273-B19","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.14309\/ajg.0000000000002947","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in ulcerative colitis: a US propensity-matched cohort study","volume":"119","author":"Kochhar","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ibd\/izad037","article-title":"Matching-adjusted indirect comparisons of filgotinib vs vedolizumab, tofacitinib, and ustekinumab for moderately to severely active ulcerative colitis","volume":"30","author":"Lu","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ueg2.12704","article-title":"Real-world comparative effectiveness and safety of filgotinib and upadacitinib for ulcerative colitis: a multicentre cohort study","volume":"12","author":"Nogami","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2026040214063208600_izaf273-B22","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1007\/s12325-024-02912-y","article-title":"Comparative efficacy and safety of upadacitinib vs vedolizumab, ustekinumab, and tofacitinib after induction and maintenance for ulcerative colitis: three matching-adjusted indirect comparisons","volume":"41","author":"Reinisch","year":"2024","journal-title":"Adv Ther"},{"key":"2026040214063208600_izaf273-B23","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00187","article-title":"Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan","author":"Tamura","year":"2025.","journal-title":"Intest Res"},{"key":"2026040214063208600_izaf273-B24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/jcm14010217","article-title":"Continuous treatment with tofacitinib but not filgotinib is effective in non-responders with active ulcerative colitis: a propensity score-matching analysis","volume":"14","author":"Yagi","year":"2025","journal-title":"J Clin Med"},{"key":"2026040214063208600_izaf273-B25","doi-asserted-by":"crossref","first-page":"jjaf021","DOI":"10.1093\/ecco-jcc\/jjaf021","article-title":"Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B26","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2022","journal-title":"Gut"},{"key":"2026040214063208600_izaf273-B27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B28","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2026040214063208600_izaf273-B29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/MEG.0000000000002751","article-title":"Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis","volume":"36","author":"Rokkas","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/jcpt.13622","article-title":"Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis","volume":"47","author":"Li","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2026040214063208600_izaf273-B31","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ueg2.12709","article-title":"Upadacitinib versus filgotinib in ulcerative colitis: is the evidence sufficient to inform treatment Decisions?","volume":"12","author":"Vuyyuru","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2026040214063208600_izaf273-B32","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/apt.17816","article-title":"Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis","volume":"59","author":"Panaccione","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/apt.17853","article-title":"Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author\u2019s reply","volume":"59","author":"Panaccione","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00508-022-02110-2","article-title":"Tofacitinib in the treatment of ulcerative colitis: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (\u00d6GGH)","volume":"135","author":"Kutschera","year":"2023","journal-title":"Wien Klin Wochenschr"},{"key":"2026040214063208600_izaf273-B37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12664-023-01507-9","article-title":"Tofacitinib use in ulcerative colitis: an expert consensus for day-to-day clinical practice","volume":"43","author":"Banerjee","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"2026040214063208600_izaf273-B38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.17829","article-title":"Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety","volume":"59","author":"Sagami","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B39","doi-asserted-by":"crossref","first-page":"e934460","DOI":"10.12659\/AJCR.934460","article-title":"Tofacitinib for a child with refractory steroid-dependent ulcerative colitis: a case report and review of the literature","volume":"22","author":"Alajmi","year":"2021","journal-title":"Am J Case Rep"},{"key":"2026040214063208600_izaf273-B40","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MPG.0000000000003616","article-title":"Tofacitinib salvage therapy for children hospitalized for corticosteroid- and biologic-refractory ulcerative colitis","volume":"75","author":"Constant","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026040214063208600_izaf273-B41","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/apt.15496","article-title":"Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease","volume":"50","author":"Dolinger","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B42","doi-asserted-by":"crossref","first-page":"e31757","DOI":"10.1097\/MD.0000000000031757","article-title":"Japanese pediatric patient with refractory steroid-resistant ulcerative colitis successfully treated with Tofacitinib: A case report","volume":"101","author":"Kakiuchi","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2026040214063208600_izaf273-B43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/ibd\/izae112","article-title":"Tofacitinib in pediatric ulcerative colitis: a retrospective multicenter experience","volume":"31","author":"Ledder","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B44","doi-asserted-by":"crossref","first-page":"e15551","DOI":"10.1111\/ped.15551","article-title":"Refractory pediatric ulcerative colitis responding to high dose tofacitinib","volume":"65","author":"Miyata","year":"2023","journal-title":"Pediatr Int"},{"key":"2026040214063208600_izaf273-B45","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/MPG.0000000000003190","article-title":"Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease","volume":"73","author":"Moore","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026040214063208600_izaf273-B46","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastrohep.2022.10.020","article-title":"Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: real world experience","volume":"46","author":"Parra-Izquierdo","year":"2023","journal-title":"Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B47","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.gastrohep.2023.09.013","article-title":"Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience","volume":"47","author":"Parra-Izquierdo","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B48","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1097\/PG9.0000000000000332","article-title":"Outcomes of tofacitinib use in an Irish pediatric cohort","volume":"4","author":"Ryan","year":"2023","journal-title":"JPGN Rep"},{"key":"2026040214063208600_izaf273-B49","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/apt.70016","article-title":"Upadacitinib for induction of remission in paediatric Crohn\u2019s disease: an international multicentre retrospective study","volume":"61","author":"Cohen","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B50","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ibd\/izad048","article-title":"Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn\u2019s disease","volume":"29","author":"Collen","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jpr3.12124","article-title":"Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments","volume":"5","author":"Dickerson","year":"2024","journal-title":"JPGN Rep"},{"key":"2026040214063208600_izaf273-B52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jpr3.12067","article-title":"Rescue therapy with upadacitinib in medically refractory pediatric ulcerative colitis","volume":"5","author":"Miller","year":"2024","journal-title":"JPGN Rep"},{"key":"2026040214063208600_izaf273-B53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jpn3.12408","article-title":"Upadacitinib is associated with clinical response and steroid-free remission for children and adolescents with inflammatory bowel disease","volume":"80","author":"Runde","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026040214063208600_izaf273-B54","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/ibd\/izad300","article-title":"Single-center experience with upadacitinib for adolescents with refractory inflammatory bowel disease","volume":"30","author":"Spencer","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B55","doi-asserted-by":"crossref","first-page":"jjae182","DOI":"10.1093\/ecco-jcc\/jjae182","article-title":"Upadacitinib for induction of remission in pediatric ulcerative colitis: an international multi\u2011center study","volume":"19","author":"Yerushalmy-Feler","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B56","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/apt.70076","article-title":"Editorial: upadacitinib-a promising induction agent for paediatric Crohn\u2019s disease?","volume":"61","author":"Stranges","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B57","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apt.12616","article-title":"Systematic review with meta-analysis: inflammatory bowel disease in the elderly","volume":"39","author":"Gisbert","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B58","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3390\/cells12131722","article-title":"Efficacy and safety of biological therapies and JAK inhibitors in older patients with inflammatory bowel disease","volume":"12","author":"Fries","year":"2023","journal-title":"Cells"},{"key":"2026040214063208600_izaf273-B59","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/bcp.13726","article-title":"Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor","volume":"84","author":"Namour","year":"2018","journal-title":"Brit J Clinical Pharma"},{"key":"2026040214063208600_izaf273-B60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","article-title":"Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication","volume":"59","author":"Mohamed","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026040214063208600_izaf273-B61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ibd\/izac084","article-title":"Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program","volume":"29","author":"Lichtenstein","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B62","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"2026040214063208600_izaf273-B63","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2026040214063208600_izaf273-B64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cgh.2020.10.004","article-title":"Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis","volume":"20","author":"Colombel","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B65","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B66","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/ibd\/izad242","article-title":"Clinical and endoscopic outcomes through 78 weeks of tofacitinib therapy for ulcerative colitis in a US cohort","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B67","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.14309\/ajg.0000000000002761","article-title":"Effectiveness of tofacitinib in patients with ulcerative colitis: a nationwide veterans administration cohort study","volume":"119","author":"Khan","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B68","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.cgh.2025.01.036","article-title":"Effectiveness and safety of tofacitinib in biologic-na\u00efve elderly patients with ulcerative colitis","volume":"23","author":"Singh","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B69","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/apt.17674","article-title":"Integrated safety analysis of filgotinib for ulcerative colitis: results from SELECTION and SELECTIONLTE","volume":"58","author":"Schreiber","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B70","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cgh.2010.03.022","article-title":"Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease","volume":"8","author":"Ha","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B71","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bpg.2018.05.007","article-title":"Acute severe ulcerative colitis: state of the art treatment","volume":"32-33","author":"Gisbert","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026040214063208600_izaf273-B72","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MOG.0000000000000637","article-title":"The management of the hospitalized ulcerative colitis patient: the medical-surgical conundrum","volume":"36","author":"Levy","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"2026040214063208600_izaf273-B73","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B74","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute severe ulcerative colitis trials: the past, the present and the future","volume":"73","author":"Honap","year":"2024","journal-title":"Gut"},{"key":"2026040214063208600_izaf273-B75","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Riviere","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B76","first-page":"2106","article-title":"Positioning tofacitinib in the treatment algorithm of moderate to severe ulcerative colitis","volume":"24","author":"Danese","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B77","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","article-title":"Tofacitinib versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: a prospective, open-label, randomized, pilot study","volume":"18","author":"Singh","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B79","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B80","doi-asserted-by":"crossref","first-page":"138","DOI":"10.14309\/ajg.0000000000001979","article-title":"Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: data from the phase 2b\/3 SELECTION trial","volume":"118","author":"Danese","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B81","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.14309\/ajg.0000000000002145","article-title":"Real-world evidence of tofacinitib in ulcerative colitis: short-term and long-term effectiveness and safety","volume":"118","author":"Chaparro","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B82","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2026040214063208600_izaf273-B83","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/apt.14665","article-title":"High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis","volume":"47","author":"Kurnool","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B84","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/apt.16456","article-title":"Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib","volume":"54","author":"Tassone","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B85","doi-asserted-by":"crossref","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2026040214063208600_izaf273-B86","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.16439","article-title":"The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme","volume":"54","author":"Farraye","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B87","doi-asserted-by":"crossref","first-page":"e002103","DOI":"10.1136\/rmdopen-2021-002103","article-title":"Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies","volume":"8","author":"Dikranian","year":"2022","journal-title":"RMD Open"},{"key":"2026040214063208600_izaf273-B88","first-page":"612","article-title":"Restarting biologic agents after a drug holiday","volume":"15","author":"Rubin","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026040214063208600_izaf273-B89","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and colitis organisation topical review on treatment withdrawal [\u2018Exit Strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B90","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B91","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ajg.2016.569","article-title":"Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study","volume":"112","author":"Casanova","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B92","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"2026040214063208600_izaf273-B93","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2026040214063208600_izaf273-B94","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bcp.13523","article-title":"Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial","volume":"84","author":"Mukherjee","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2026040214063208600_izaf273-B95","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/ecco-jcc\/jjab065","article-title":"Efficacy and safety of tofacitinib re-treatment for ulcerative colitis after treatment interruption: results from the OCTAVE clinical trials","volume":"15","author":"Pan\u00e9s","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B96","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jgh.16386","article-title":"Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain","volume":"39","author":"Allegretti","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B97","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/ecco-jcc\/jjad123","article-title":"Withdrawal and re-treatment with filgotinib in ulcerative colitis: post hoc analyses of the phase 2b\/3 SELECTION and SELECTIONLTE studies","volume":"18","author":"Vermeire","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B98","doi-asserted-by":"crossref","first-page":"otaf020","DOI":"10.1093\/crocol\/otaf020","article-title":"Clinical outcomes for patients with ulcerative colitis in cases of withdrawal and resumption of janus kinase inhibitors: multicenter cohort study","volume":"7","author":"Sano","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"2026040214063208600_izaf273-B99","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"2026040214063208600_izaf273-B100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B101","first-page":"97","article-title":"Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series","volume":"36","author":"Komeda","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"2026040214063208600_izaf273-B102","first-page":"e45416","article-title":"Tofacitinib in steroid-refractory acute severe ulcerative colitis: a retrospective analysis","volume":"15","author":"Malakar","year":"2023","journal-title":"Cureus"},{"key":"2026040214063208600_izaf273-B103","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5217\/ir.2024.00003","article-title":"P. What to do when traditional rescue therapies fail in acute severe ulcerative colitis","volume":"22","author":"Suen","year":"2024","journal-title":"Intest Res"},{"key":"2026040214063208600_izaf273-B104","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/ibd\/izab087","article-title":"Tofacitinib in acute severe ulcerative colitis: case series and a systematic review","volume":"27","author":"Jena","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B105","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.dld.2023.05.021","article-title":"The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: a systematic review","volume":"55","author":"Mpakogiannis","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026040214063208600_izaf273-B106","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: a systematic review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B107","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae111","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a systemic review and network meta-analysis","author":"Huang","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B108","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ibd\/izae191","article-title":"Upadacitinib for acute severe ulcerative colitis: a systematic review","volume":"31","author":"Damianos","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000545263","article-title":"Filgotinib to treat acute severe refractory ulcerative colitis: a case report and review of the literature","volume":"19","author":"Vespere","year":"2025","journal-title":"Case Rep Gastroenterol"},{"key":"2026040214063208600_izaf273-B110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2026040214063208600_izaf273-B111","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ecco-jcc\/jjaa028","article-title":"Tofacitinib for acute severe colitis: when the going gets tough, the tough get going","volume":"14","author":"D\u2019Amico","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B112","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12664-024-01522-4","article-title":"Modern practical management of acute severe colitis","volume":"43","author":"AbdelMeguid","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"2026040214063208600_izaf273-B113","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/codi.15702","article-title":"Perioperative safety of tofacitinib in surgical ulcerative colitis patients","volume":"23","author":"Lightner","year":"2021","journal-title":"Colorectal Dis"},{"key":"2026040214063208600_izaf273-B114","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/DCR.0000000000003137","article-title":"Tofacitinib is associated with increased risk of postoperative venous thromboembolism in patients with ulcerative colitis","volume":"67","author":"Russell","year":"2024","journal-title":"Dis Colon Rectum"},{"key":"2026040214063208600_izaf273-B115","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","article-title":"Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis","volume":"19","author":"Deepak","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2022.04.050","article-title":"PUCCINI: safety of anti-TNF in the perioperative setting","volume":"163","author":"Hyman","year":"2022","journal-title":"Gastroenterology"},{"key":"2026040214063208600_izaf273-B117","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/DCR.0000000000003440","article-title":"Tofacitinib exposure does not increase postoperative complications among patients with ulcerative colitis undergoing total colectomy: a retrospective case-control study","volume":"67","author":"Gomaa","year":"2024","journal-title":"Dis Colon Rectum"},{"key":"2026040214063208600_izaf273-B118","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.14309\/ajg.0000000000002676","article-title":"Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study","volume":"119","author":"Dragoni","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B119","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000544062","article-title":"No increased risk of venous thromboembolism or infectious complications after janus kinase inhibitor exposure in patients with ulcerative colitis undergoing surgery","volume":"43","author":"De Greef","year":"2025","journal-title":"Dig Dis"},{"key":"2026040214063208600_izaf273-B120","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B121","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.01.032","article-title":"Postoperative outcomes in tofacitinib-treated patients with acute severe ulcerative colitis undergoing colectomy","author":"Larson","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B122","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B123","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14072232","article-title":"Real-world effectiveness and safety of upadacitinib in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Taxonera","year":"2025","journal-title":"J Clin Med"},{"key":"2026040214063208600_izaf273-B124","doi-asserted-by":"crossref","first-page":"e940966","DOI":"10.12659\/AJCR.940966","article-title":"Upadacitinib as a rescue therapy in acute severe ulcerative colitis: a case report and review of the literature","volume":"24","author":"Ali","year":"2023","journal-title":"Am J Case Rep"},{"key":"2026040214063208600_izaf273-B125","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/apt.17961","article-title":"Efficacy and safety of filgotinib for ulcerative colitis: a real-world multicenter retrospective study in Japan","volume":"59","author":"Akiyama","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B126","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience","author":"Berinstein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B127","doi-asserted-by":"crossref","first-page":"e01673","DOI":"10.14309\/crj.0000000000001673","article-title":"Upadacitinib monotherapy after tofacitinib failure was successful for induction but not maintenance of remission in medically refractory ulcerative colitis","volume":"12","author":"Chatto","year":"2025","journal-title":"ACG Case Rep J"},{"key":"2026040214063208600_izaf273-B128","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ecco-jcc\/jjac157","article-title":"Multicentre real-world experience of upadacitinib in the treatment of Crohn\u2019s disease","volume":"17","author":"Chugh","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B129","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ibd\/izad155","article-title":"Clinical and endoscopic outcomes after upadacitinib induction for ulcerative colitis: a multicenter retrospective cohort study","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B130","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.cgh.2025.01.012","article-title":"Real-world effectiveness and safety of upadacitinib in Crohn\u2019s disease: a multicenter study","volume":"23","author":"Devi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B131","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B132","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.14309\/ajg.0000000000003243","article-title":"Persistence, effectiveness, and safety of upadacitinib in Crohn\u2019s disease and ulcerative colitis in real life: results from a spanish nationwide study (Ureal Study)","volume":"120","author":"Garc\u00eda","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B133","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5217\/ir.2024.00127","article-title":"Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study","volume":"23","author":"Gilmore","year":"2025","journal-title":"Intest Res"},{"key":"2026040214063208600_izaf273-B134","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2169\/internalmedicine.2653-23","article-title":"Efficacy of upadacitinib as a second-line JAK inhibitor in ulcerative colitis: a case series","volume":"63","author":"Hosomi","year":"2024","journal-title":"Intern Med"},{"key":"2026040214063208600_izaf273-B135","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002157","article-title":"Upadacitinib results in endoscopic remission in patients with inflammatory bowel disease and prior tofacitinib failure","author":"Lee","journal-title":"J Clin Gastroenterol"},{"key":"2026040214063208600_izaf273-B136","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/ibd\/izad279","article-title":"Use of upadacitinib in 16 tofacitinib-refractory ulcerative colitis patients: a single-center case 2series","volume":"30","author":"Levine","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B137","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1007\/s10620-024-08630-3","article-title":"Response to upadacitinib in patients with inflammatory bowel disease previously treated with tofacitinib","volume":"69","author":"Odah","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026040214063208600_izaf273-B138","doi-asserted-by":"crossref","first-page":"2024-11-1","DOI":"10.7573\/dic.2024-11-1","article-title":"Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres","volume":"14","author":"Young","year":"2025","journal-title":"Drugs Context"},{"key":"2026040214063208600_izaf273-B139","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keac285","article-title":"Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy","volume":"62","author":"Amstad","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026040214063208600_izaf273-B140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard-2022-222835","article-title":"After JAK inhibitor failure: to cycle or to switch, that is the question\u2014data from the JAK-pot collaboration of registries","volume":"82","author":"Pombo-Suarez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026040214063208600_izaf273-B141","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-021-04075-0","article-title":"Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"12","author":"Ebina","year":"2022","journal-title":"Sci Rep"},{"key":"2026040214063208600_izaf273-B142","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1021\/acsomega.1c06715","article-title":"Unraveling the molecular mechanism of recognition of selected next-generation antirheumatoid arthritis inhibitors by Janus Kinase 1","volume":"7","author":"Sk","year":"2022","journal-title":"ACS Omega"},{"key":"2026040214063208600_izaf273-B143","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signaling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026040214063208600_izaf273-B144","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026040214063208600_izaf273-B145","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026040214063208600_izaf273-B146","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B147","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn\u2019s disease in the CELEST extension study","volume":"20","author":"D\u2019Haens","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B148","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn\u2019s disease: a UK multicentre retrospective cohort study","volume":"15","author":"Elford","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"2026040214063208600_izaf273-B149","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3748\/wjg.v30.i13.1871","article-title":"Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis","volume":"30","author":"Kojima","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2026040214063208600_izaf273-B150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000545704","article-title":"Investigation of the clinical remission course in ulcerative colitis from tofacitinib induction to tapering or withdrawal in Japanese patients: a single-center retrospective study","volume":"10","author":"Koroku","year":"2025","journal-title":"Inflamm Intest Dis"},{"key":"2026040214063208600_izaf273-B151","doi-asserted-by":"crossref","first-page":"861","DOI":"10.14309\/ajg.0000000000002129","article-title":"REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD research consortium multicenter national cohort study","volume":"118","author":"Ma","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B152","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.dld.2023.08.061","article-title":"Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study","volume":"56","author":"Macaluso","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026040214063208600_izaf273-B153","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.cgh.2023.05.001","article-title":"Real-world experience with tofacitinib dose de-escalation in patients with moderate and severe ulcerative colitis","volume":"21","author":"Yu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B154","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1007\/s10620-013-2830-7","article-title":"Health care costs of complex perianal fistula in Crohn\u2019s disease","volume":"58","author":"Chaparro","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2026040214063208600_izaf273-B155","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/ecco-jcc\/jjad008","article-title":"Pathogenesis of perianal fistulising Crohn\u2019s disease: current knowledge, gaps in understanding, and future research directions","volume":"17","author":"Cao","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B156","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/MIB.0000000000000705","article-title":"Perianal Crohn\u2019s disease is associated with distal colonic disease, stricturing disease behavior, IBD-associated serologies and genetic variation in the JAK-STAT pathway","volume":"22","author":"Kaur","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B157","doi-asserted-by":"crossref","first-page":"e01623","DOI":"10.14309\/crj.0000000000001623","article-title":"Rapid resolution of perianal Crohn\u2019s disease with upadacitinib","volume":"12","author":"Brennan","year":"2025","journal-title":"ACG Case Rep J"},{"key":"2026040214063208600_izaf273-B158","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cgh.2024.08.032","article-title":"Efficacy and safety of upadacitinib for perianal fistulizing Crohn\u2019s disease: a post hoc analysis of 3 phase 3 trials","volume":"23","author":"Colombel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B159","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjae003","article-title":"Efficacy and safety of filgotinib for the treatment of perianal fistulising Crohn\u2019s disease [DIVERGENCE 2]: a phase 2, randomised, placebo-controlled trial","volume":"18","author":"Reinisch","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B160","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"2026040214063208600_izaf273-B161","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dld.2022.08.039","article-title":"Colectomy rates in ulcerative colitis: a systematic review and meta-analysis","volume":"55","author":"Dai","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026040214063208600_izaf273-B162","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/apt.13905","article-title":"Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm","volume":"45","author":"Segal","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B163","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2208450","article-title":"Vedolizumab for the Treatment of Chronic Pouchitis","volume":"388","author":"Travis","year":"2023","journal-title":"N Engl J Med"},{"key":"2026040214063208600_izaf273-B164","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ueg2.12683","article-title":"Tofacitinib for the treatment of chronic pouchitis: a pilot study","volume":"13","author":"de Jong","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"2026040214063208600_izaf273-B165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/ibd\/izae116","article-title":"Treatment of chronic pouchitis with JAK inhibitors: results from a large multicenter database","volume":"31","author":"Alsakarneh","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B166","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/ecco-jcc\/jjad207","article-title":"Tofacitinib in chronic inflammatory pouch diseases: a systematic review","volume":"18","author":"Cataletti","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B167","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/ibd\/izac147","article-title":"Tofacitinib for the treatment of pouch-related disorders: a case series","volume":"28","author":"Dalal","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B168","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.gastrohep.2022.08.005","article-title":"Tofacitinib for the treatment of inflammatory condition of the ileoanal pouch refractory to infliximab","volume":"46","author":"Fortuny","year":"2023","journal-title":"Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B169","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1002\/deo2.415","article-title":"Duodenitis associated with ulcerative colitis and pouchitis after total colectomy successfully treated with upadacitinib: a case report","volume":"5","author":"Kojima","year":"2025","journal-title":"DEN Open"},{"key":"2026040214063208600_izaf273-B170","doi-asserted-by":"crossref","first-page":"e01245","DOI":"10.14309\/crj.0000000000001245","article-title":"Efficacy and safety of upadacitinib in the treatment of chronic pouchitis, cuffitis, and crohn\u2019s disease of the pouch","volume":"11","author":"Lan","year":"2024","journal-title":"ACG Case Rep J"},{"key":"2026040214063208600_izaf273-B171","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12328-020-01108-5","article-title":"A case of refractory chronic pouchitis successfully treated with tofacitinib","volume":"13","author":"Okano","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"2026040214063208600_izaf273-B172","doi-asserted-by":"crossref","first-page":"e01442","DOI":"10.14309\/crj.0000000000001442","article-title":"Successful outcome treating pyoderma gangrenosum and pouchitis with upadacitinib","volume":"11","author":"Prieto Jimenez","year":"2024","journal-title":"ACG Case Rep J"},{"key":"2026040214063208600_izaf273-B173","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ecco-jcc\/jjad194","article-title":"Treatment of antibiotic refractory chronic pouchitis with JAK inhibitors and S1P receptor modulators: An ECCO CONFER multicentre case series","volume":"18","author":"Ribaldone","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B174","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/ibd\/izad191","article-title":"Effectiveness of oral tofacitinib in chronic pouchitis: a prospective, open-label pilot study","volume":"30","author":"Syal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B175","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.dld.2023.04.028","article-title":"Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics","volume":"55","author":"Uzzan","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026040214063208600_izaf273-B176","doi-asserted-by":"crossref","first-page":"jjaf161","DOI":"10.1093\/ecco-jcc\/jjaf161","article-title":"Combination therapy with biologics and\/or small molecules in inflammatory bowel disease: a comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B177","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/diseases10040102","article-title":"Effectiveness of dual biologic or small molecule therapy for achieving endoscopic remission in refractory inflammatory bowel disease","volume":"10","author":"Abdullah","year":"2022","journal-title":"Diseases"},{"key":"2026040214063208600_izaf273-B178","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/ibd\/izab112","article-title":"Effectiveness and safety of combining tofacitinib with a biologic in patients with refractory inflammatory bowel diseases","volume":"27","author":"Alayo","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B179","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.cgh.2020.08.023","article-title":"Reply","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B180","first-page":"766","article-title":"Upadacitinib and ustekinumab combination treatment for a refractory case of spondyloarthritis and Crohn\u2019s disease","volume":"42","author":"Bianchi","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2026040214063208600_izaf273-B181","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","article-title":"Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease","volume":"27","author":"Dolinger","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B182","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cgh.2020.07.046","article-title":"Tofacitinib is safe and effective when used in combination with infliximab for the management of refractory ulcerative Colitis","volume":"19","author":"Gilmore","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B183","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J Dig Dis"},{"key":"2026040214063208600_izaf273-B184","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ueg2.12170","article-title":"Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: a European retrospective observational study","volume":"9","author":"Goessens","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2026040214063208600_izaf273-B185","article-title":"Dual biologic or small molecule therapy in pediatric inflammatory bowel disease: a single center experience","volume":"12","author":"Guo","year":"2025","journal-title":"Children (Basel)"},{"key":"2026040214063208600_izaf273-B186","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1093\/ibd\/izab095","article-title":"Combined targeted treatment using biologic-tofacitinib co-therapy in chronic active ulcerative colitis","volume":"27","author":"Hilley","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B187","doi-asserted-by":"crossref","first-page":"17562848241307598","DOI":"10.1177\/17562848241307598","article-title":"Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China","volume":"18","author":"Jin","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"2026040214063208600_izaf273-B188","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/ibd\/izab028","article-title":"Combining therapies in inflammatory bowel disease: end of the line or a new era?","volume":"27","author":"Judge","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B189","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1007\/s10620-024-08379-9","article-title":"Real-world outcomes of dual advanced therapy in children and young adults with inflammatory bowel disease","volume":"69","author":"Kellar","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026040214063208600_izaf273-B190","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","article-title":"Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy","volume":"17","author":"Le Berre","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B191","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1093\/ibd\/izaa158","article-title":"Treatment of ulcerative colitis and seronegative inflammatory spondyloarthritis with vedolizumab and tofacitinib","volume":"26","author":"Lee","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B192","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ibd\/izab176","article-title":"Safety and efficacy of tofacitinib in combination with biologic therapy for refractory Crohn\u2019s disease","volume":"28","author":"Lee","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B193","doi-asserted-by":"crossref","first-page":"otab030","DOI":"10.1093\/crocol\/otab030","article-title":"Favorable outcomes combining vedolizumab with other biologics or tofacitinib for treatment of inflammatory bowel disease","volume":"3","author":"Llano","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"2026040214063208600_izaf273-B194","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.dld.2024.08.055","article-title":"Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease","volume":"57","author":"McShane","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026040214063208600_izaf273-B195","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.2147\/JIR.S511309","article-title":"Advanced combination therapy with biologics and upadacitinib in refractory inflammatory bowel disease: a retrospective study from Taiwan","volume":"18","author":"Meng","year":"2025","journal-title":"J Inflamm Res"},{"key":"2026040214063208600_izaf273-B196","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","article-title":"Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn\u2019s disease","volume":"69","author":"Miyatani","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026040214063208600_izaf273-B197","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ejhpharm-2020-002437","article-title":"A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib","volume":"28","author":"Taberner Bonastre","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"2026040214063208600_izaf273-B198","doi-asserted-by":"crossref","first-page":"1283251","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"key":"2026040214063208600_izaf273-B199","doi-asserted-by":"crossref","first-page":"e00226","DOI":"10.14309\/crj.0000000000000226","article-title":"Use of tofacitinib for the treatment of arthritis associated with ulcerative colitis","volume":"6","author":"Wang","year":"2019","journal-title":"ACG Case Rep J"},{"key":"2026040214063208600_izaf273-B200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ibd\/izad064","article-title":"Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): a multicenter study from the pediatric IBD porto group of ESPGHAN","volume":"30","author":"Yerushalmy-Feler","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B201","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/ibd\/izae105","article-title":"Short-term use of upadacitinib in combination with biologic therapy for inducing clinical remission in patients with active inflammatory bowel disease","volume":"30","author":"Yin","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B202","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/1744666X.2022.2104713","article-title":"Could small molecules be used in combination with biologics for inflammatory bowel disease?","volume":"18","author":"D\u2019Amico","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2026040214063208600_izaf273-B203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B204","doi-asserted-by":"crossref","first-page":"17562848211005708","DOI":"10.1177\/17562848211005708","article-title":"Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis","volume":"14","author":"Rubin","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2026040214063208600_izaf273-B205","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/apt.70181","article-title":"The effectiveness of medical therapies for joint, skin and eye extraintestinal manifestations in IBD-an umbrella review","volume":"61","author":"Nardone","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B206","doi-asserted-by":"crossref","first-page":"108517","DOI":"10.1016\/j.intimp.2022.108517","article-title":"Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review","volume":"105","author":"Wang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2026040214063208600_izaf273-B207","first-page":"134","article-title":"Atypical COVID-19-related erythema nodosum in a patient with ulcerative colitis treated with upadacitinib","author":"Mahadea","year":"2024","journal-title":"Pol Arch Intern Med"},{"key":"2026040214063208600_izaf273-B208","doi-asserted-by":"crossref","first-page":"e15963","DOI":"10.1111\/dth.15963","article-title":"A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib","volume":"35","author":"Nakamura","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026040214063208600_izaf273-B209","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/ibd\/izz015","article-title":"Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab","volume":"25","author":"Gregory","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B210","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B211","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/ced.14683","article-title":"Tofacitinib for the treatment of refractory pyoderma gangrenosum","volume":"46","author":"Orfaly","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2026040214063208600_izaf273-B212","doi-asserted-by":"crossref","first-page":"e01531","DOI":"10.14309\/crj.0000000000001531","article-title":"Successful treatment of severe pyoderma gangrenosum and ulcerative colitis with upadacitinib","volume":"11","author":"Park","year":"2024","journal-title":"ACG Case Rep J"},{"key":"2026040214063208600_izaf273-B213","first-page":"733","article-title":"Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient","volume":"113","author":"Salm\u00f3n Olavarr\u00eda","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"2026040214063208600_izaf273-B214","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1093\/ibd\/izab005","article-title":"Tofacitinib for the treatment of three immune-mediated conditions in one patient: ulcerative colitis, pyoderma gangrenosum, and alopecia areata","volume":"27","author":"Sedano","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B215","doi-asserted-by":"crossref","first-page":"446","DOI":"10.14740\/jocmr5005","article-title":"Upadacitinib plus intensive granulocyte and monocyte adsorptive apheresis for ulcerative colitis achieved ulcer healing for pyoderma gangrenosum","volume":"15","author":"Tanida","year":"2023","journal-title":"J Clin Med Res"},{"key":"2026040214063208600_izaf273-B216","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1093\/ibd\/izab181","article-title":"Success of cyclosporin and tofacitinib combination therapy in a patient with severe steroid-refractory ulcerative colitis","volume":"27","author":"Yang","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B217","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.abd.2024.10.007","article-title":"Efficacy of upadacitinib in the management of atopic dermatitis, Crohn\u2019s disease, and hidradenitis suppurativa: one treatment, multiple indications","volume":"100","author":"Bueno-Filho","year":"2025","journal-title":"An Bras Dermatol"},{"key":"2026040214063208600_izaf273-B218","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/pde.15759","article-title":"The successful use of upadacitinib as monotherapy for hidradenitis suppurativa and ulcerative colitis in the setting of refractory disease","volume":"42","author":"Ok","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"2026040214063208600_izaf273-B219","article-title":"Atopic dermatitis and ulcerative colitis successfully treated with upadacitinib","volume":"59","author":"Grieco","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026040214063208600_izaf273-B220","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/jdv.19377","article-title":"Upadacitinib in concurrent Crohn\u2019s disease, atopic dermatitis and alopecia areata: A case report","volume":"38","author":"Novielli","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026040214063208600_izaf273-B221","doi-asserted-by":"crossref","first-page":"e00690","DOI":"10.14309\/crj.0000000000000690","article-title":"Treatment of Crohn\u2019s disease and concomitant alopecia areata with tofacitinib","volume":"8","author":"Akiyama","year":"2021","journal-title":"ACG Case Rep J"},{"key":"2026040214063208600_izaf273-B222","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s12328-020-01150-3","article-title":"Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata","volume":"13","author":"Kikuchi","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"2026040214063208600_izaf273-B223","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdcr.2020.10.027","article-title":"Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease","volume":"7","author":"Peterson","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2026040214063208600_izaf273-B224","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12668-022-01027-4","article-title":"Clinical Case of tofacitinib therapy in autoimmune alopecia in patient with ulcerative colitis","volume":"12","author":"Bodryagina","year":"2022","journal-title":"Bionanoscience"},{"key":"2026040214063208600_izaf273-B225","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1093\/ibd\/izaa243","article-title":"Tofacitinib for the treatment of ulcerative colitis, alopecia universalis, and atopic dermatitis: one drug, three diseases","volume":"27","author":"Honap","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B226","doi-asserted-by":"crossref","first-page":"2050313x231160914","DOI":"10.1177\/2050313X231160914","article-title":"Successful treatment of concomitant alopecia universalis and Crohn\u2019s disease with upadacitinib: a case report","volume":"11","author":"Johnston","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"2026040214063208600_izaf273-B227","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/imj.16484","article-title":"Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib","volume":"54","author":"Yiu","year":"2024","journal-title":"Intern Med J"},{"key":"2026040214063208600_izaf273-B228","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1111\/1346-8138.17282","article-title":"A case of erosive pustular dermatosis of the scalp with ulcerative colitis successfully treated with upadacitinib","volume":"51","author":"Sugiura","year":"2024","journal-title":"J Dermatol"},{"key":"2026040214063208600_izaf273-B229","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.12998\/wjcc.v8.i24.6389","article-title":"Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report","volume":"8","author":"Komeda","year":"2020","journal-title":"World J Clin Cases"},{"key":"2026040214063208600_izaf273-B230","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/annrheumdis-2019-216606","article-title":"Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis","volume":"79","author":"Kuwabara","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026040214063208600_izaf273-B231","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kez580","article-title":"A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib","volume":"59","author":"Sato","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026040214063208600_izaf273-B232","doi-asserted-by":"crossref","first-page":"e797","DOI":"10.1111\/jdv.18276","article-title":"Improvement of redness and hyperkeratosis in a case of Nagashima-type palmoplantar keratosis during Tofacitinib treatment for ulcerative colitis","volume":"36","author":"Shiiya","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026040214063208600_izaf273-B233","doi-asserted-by":"crossref","first-page":"e01342","DOI":"10.14309\/crj.0000000000001342","article-title":"Refractory ulcerative colitis with associated synovitis, acne, pustulosis, hyperostosis, osteitis syndrome successfully treated with tofacitinib","volume":"11","author":"Kim","year":"2024","journal-title":"ACG Case Rep J"},{"key":"2026040214063208600_izaf273-B234","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.arbr.2019.08.006","article-title":"Ulcerative colitis and bronchiectasis: can treatment with tofacitinib have an impact on respiratory symptoms?","volume":"56","author":"Le\u00f3n-Rom\u00e1n","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"2026040214063208600_izaf273-B235","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2024.02.017","article-title":"Resolution of metastatic cutaneous Crohn\u2019s disease with upadacitinib monotherapy","volume":"46","author":"Burningham","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2026040214063208600_izaf273-B236","first-page":"401","article-title":"Treatment of genital Crohn\u2019s disease with upadacitinib in a male child: a case report","volume":"19","author":"Bousvaros","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026040214063208600_izaf273-B237","doi-asserted-by":"crossref","first-page":"e0306548","DOI":"10.1371\/journal.pone.0306548","article-title":"Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with Janus kinase inhibitors: a systematic review and meta-analysis","volume":"19","author":"Ouranos","year":"2024","journal-title":"PLoS One"},{"key":"2026040214063208600_izaf273-B238","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/infdis\/jis269","article-title":"Risk of tuberculosis reactivation with tofacitinib (CP-690550)","volume":"205","author":"Maiga","year":"2012","journal-title":"J Infect Dis"},{"key":"2026040214063208600_izaf273-B239","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026040214063208600_izaf273-B240","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"2026040214063208600_izaf273-B241","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B242","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/apt.16619","article-title":"Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis","volume":"55","author":"Rubin","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B243","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B244","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B245","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/ibd\/izab234","article-title":"Tubercular pleural effusion in a patient of ulcerative colitis treated with tofacitinib","volume":"28","author":"Mishra","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B246","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ecco-jcc\/jjab200","article-title":"Disseminated tuberculosis in a patient treated with tofacitinib for ulcerative colitis","volume":"16","author":"Charpy","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B247","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.3346\/jkms.2022.37.e123","article-title":"The comparative risk of serious adverse events with tofacitinib and TNF inhibitors in patients with ulcerative colitis: the Korean experience as revealed by a national database","volume":"37","author":"Seo","year":"2022","journal-title":"J Korean Med Sci"},{"key":"2026040214063208600_izaf273-B248","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ibd\/izaa227","article-title":"Lipid profiles in patients with ulcerative colitis receiving tofacitinib-implications for cardiovascular risk and patient management","volume":"27","author":"Sands","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B249","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026040214063208600_izaf273-B250","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026040214063208600_izaf273-B251","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10067-022-06064-8","article-title":"Correction to: effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis","volume":"41","author":"Li","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026040214063208600_izaf273-B252","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B253","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2026040214063208600_izaf273-B254","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2026040214063208600_izaf273-B255","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1093\/ibd\/izaa295","article-title":"Lipid profiles in patients with ulcerative colitis receiving tofacitinib-implications for cardiovascular risk and patient management","volume":"27","author":"Sleutjes","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B256","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MEG.0b013e328325d42b","article-title":"Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease","volume":"21","author":"Koutroubakis","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B257","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.crohns.2014.01.026","article-title":"Bolus administration of steroid therapy is more favorable than the conventional use in preventing decrease of bone density and the increase of body fat percentage in patients with inflammatory bowel disease","volume":"8","author":"Farkas","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B258","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/00365521.2013.848231","article-title":"Long-term increase in serum cholesterol levels in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications","volume":"49","author":"B\u00e1lint","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2026040214063208600_izaf273-B259","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026040214063208600_izaf273-B260","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of new biologics (Vedolizumab and Ustekinumab) and small molecules (Tofacitinib) during pregnancy: a review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"2026040214063208600_izaf273-B261","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and colitis guidelines on sexuality, fertility, pregnancy, and lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026040214063208600_izaf273-B262","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B263","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40261-024-01353-3","article-title":"Experience of tofacitinib use in pregnancy in patients with ulcerative colitis","volume":"44","author":"Chaparro","year":"2024","journal-title":"Clin Drug Investig"},{"key":"2026040214063208600_izaf273-B264","doi-asserted-by":"crossref","first-page":"e8764","DOI":"10.1002\/ccr3.8764","article-title":"First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review","volume":"12","author":"Arzivian","year":"2024","journal-title":"Clin Case Rep"},{"key":"2026040214063208600_izaf273-B265","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","article-title":"Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports","volume":"47","author":"Mahadevan","year":"2024","journal-title":"Drug Saf"},{"key":"2026040214063208600_izaf273-B266","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/ibd\/izaf027","article-title":"Placental transfer of upadacitinib among pregnant women with inflammatory bowel disease","volume":"31","author":"Ehrlich","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B267","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S2468-1253(23)00158-9","article-title":"Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis","volume":"8","author":"Julsgaard","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040214063208600_izaf273-B268","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/apt.14449","article-title":"Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis","volume":"47","author":"Bonovas","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B269","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B270","first-page":"572","article-title":"Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis","volume":"31","author":"Paschos","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2026040214063208600_izaf273-B271","doi-asserted-by":"crossref","first-page":"e000302","DOI":"10.1136\/bmjgast-2019-000302","article-title":"Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation","volume":"6","author":"Lohan","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"2026040214063208600_izaf273-B272","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"Ma","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063208600_izaf273-B273","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/2050640619883566","article-title":"Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses","volume":"7","author":"Pantavou","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"2026040214063208600_izaf273-B274","doi-asserted-by":"crossref","first-page":"17562848211064004","DOI":"10.1177\/17562848211064004","article-title":"Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Lucaciu","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2026040214063208600_izaf273-B275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063208600_izaf273-B276","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dld.2021.04.018","article-title":"Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: a single-arm meta-analysis of observational studies","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2026040214063208600_izaf273-B277","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1097\/MCG.0000000000001608","article-title":"Effectiveness and safety of tofacitinib for ulcerative colitis: systematic review and meta-analysis","volume":"56","author":"Taneja","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"2026040214063208600_izaf273-B278","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.14309\/ajg.0000000000002263","article-title":"Comparative speed of early symptomatic remission with advanced therapies for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"118","author":"Ahuja","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026040214063208600_izaf273-B279","doi-asserted-by":"crossref","first-page":"101866","DOI":"10.1016\/j.eclinm.2023.101866","article-title":"Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"57","author":"Attauabi","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026040214063208600_izaf273-B280","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"key":"2026040214063208600_izaf273-B281","doi-asserted-by":"crossref","first-page":"e001347","DOI":"10.1136\/bmjgast-2024-001347","article-title":"Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies","volume":"11","author":"Lin","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"2026040214063208600_izaf273-B282","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40261-024-01364-0","article-title":"Systematic review with meta-analysis: efficacy and safety of upadacitinib in managing moderate-to-severe Crohn\u2019s disease and ulcerative colitis","volume":"44","author":"Niu","year":"2024","journal-title":"Clin Drug Investig"},{"key":"2026040214063208600_izaf273-B283","doi-asserted-by":"crossref","first-page":"111229","DOI":"10.1016\/j.intimp.2023.111229","article-title":"Effectiveness and safety of upadacitinib for inflammatory bowel disease: a systematic review and meta-analysis of RCT and real-world observational studies","volume":"126","author":"Zheng","year":"2024","journal-title":"Int Immunopharmacol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/775\/66104003\/izaf273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/775\/66104003\/izaf273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:07:09Z","timestamp":1775153229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/4\/775\/8401349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":283,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,22]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf273","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,22]]}}}